Zenlabs Ethica Ltd
NSE: BSE: 530697
₹20.40
(-6.59%)
Sun, 15 Mar 2026, 10:26 pm
Market Cap0
PE Ratio0
Dividend0
Health Technology
Pharmaceuticals: Generic
24.5KZenlabs Ethica Analysis
dividend
- Unable to evaluate Zenlabs Ethica's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Zenlabs Ethica's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Zenlabs Ethica is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Zenlabs Ethica has been profitable on average in the past, therefore cash runway is not a concern.
- Zenlabs Ethica has been profitable on average in the past, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (163.1%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 65x debt.
- Zenlabs Ethica's cash and other short term assets cover its long term commitments.
- Zenlabs Ethica's level of debt (6.1%) compared to net worth is satisfactory (less than 40%).
- Low level of unsold assets.
management
- The tenure for the Zenlabs Ethica board of directors is about average.
- Sanjeev's compensation has been consistent with company performance over the past year, both up more than 20%.
- The tenure for the Zenlabs Ethica management team is about average.
- Sanjeev's remuneration is higher than average for companies of similar size in India.
misc
- Zenlabs Ethica is not covered by any analysts.
- Zenlabs Ethica has significant price volatility in the past 3 months.
past
- Unable to compare Zenlabs Ethica's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Zenlabs Ethica does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
- It is difficult to establish if Zenlabs Ethica has efficiently used its assets last year compared to the IN Healthcare industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Zenlabs Ethica improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
- It is difficult to establish if Zenlabs Ethica has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- Unable to compare Zenlabs Ethica's 1-year growth to the IN Healthcare industry average as it is not currently profitable.
value
- Zenlabs Ethica is good value based on assets compared to the IN Healthcare industry average.
- Zenlabs Ethica's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Zenlabs Ethica's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Zenlabs Ethica is loss making, we can't compare its value to the IN Healthcare industry average.
- Zenlabs Ethica is loss making, we can't compare the value of its earnings to the India market.
- 530697 underperformed the Healthcare industry which returned 9.1% over the past year.
- 530697 underperformed the Market in India which returned -14.5% over the past year.
- BSE:530697 is down -8.8% underperforming the Healthcare industry which returned 5.4% over the past month.
- BSE:530697 is down -8.8% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800